337 related articles for article (PubMed ID: 27704333)
21. Safety of anticoagulant treatment in cancer patients.
Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
[TBL] [Abstract][Full Text] [Related]
22. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
23. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Bdair F; Schünemann HJ
Cancer; 2008 Oct; 113(7):1685-94. PubMed ID: 18720360
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs.
Poli D; Antonucci E; Vignini E; Martinese L; Testa S; Simioni P; Pengo V; Pignatelli P; Falanga A; Masciocco L; Barcellona D; Ciampa A; Chiarugi P; Paparo C; Ageno W; Palareti G;
Eur J Intern Med; 2020 Oct; 80():73-77. PubMed ID: 32522446
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Bleker SM; Brekelmans MPA; Eerenberg ES; Cohen AT; Middeldorp S; Raskob G; Büller HR
Thromb Haemost; 2017 Oct; 117(10):1944-1951. PubMed ID: 28816341
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
27. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
Chai-Adisaksopha C; Linkins LA; ALKindi SY; Cheah M; Crowther MA; Iorio A
Thromb Haemost; 2017 Feb; 117(3):589-594. PubMed ID: 28078351
[TBL] [Abstract][Full Text] [Related]
31. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
[TBL] [Abstract][Full Text] [Related]
32. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
33. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
J Exp Clin Cancer Res; 2008 Jul; 27(1):21. PubMed ID: 18634550
[TBL] [Abstract][Full Text] [Related]
34. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
35. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases.
Alvarado G; Noor R; Bassett R; Papadopoulos NE; Kim KB; Hwu WJ; Bedikian A; Patel S; Hwu P; Davies MA
Melanoma Res; 2012 Aug; 22(4):310-5. PubMed ID: 22584956
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.
Lin RJ; Green DL; Shah GL
Oncologist; 2018 Apr; 23(4):468-473. PubMed ID: 29158366
[TBL] [Abstract][Full Text] [Related]
37. Gender differences in patients with venous thromboembolism and five common sites of cancer.
Martín-Martos F; Trujillo-Santos J; Del Toro J; Bura-Riviere A; Lorenzo A; Barillari G; Soler S; Mahè I; Sahuquillo JC; Monreal M;
Thromb Res; 2017 Mar; 151 Suppl 1():S16-S20. PubMed ID: 28262228
[TBL] [Abstract][Full Text] [Related]
38. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.
Diaz M; Jo J
Curr Oncol Rep; 2022 Apr; 24(4):493-500. PubMed ID: 35179708
[TBL] [Abstract][Full Text] [Related]
39. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis.
Zhou Z; Yu J; Carcel C; Delcourt C; Shan J; Lindley RI; Neal B; Anderson CS; Hackett ML
BMJ Open; 2018 May; 8(5):e019672. PubMed ID: 29764874
[TBL] [Abstract][Full Text] [Related]
40. Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?
Qayyum F; Holbrook A; Lam J; Kovacs MJ; Schulman S
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):705-13. PubMed ID: 23080362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
